Isotechnika to be featured on 21st Century Health TV series

Isotechnika Pharma (ISA:TSX) will be featured on 21stCentury Health, an award winning targeted business show that features business leaders across the world and airs on various national cable networks  that are viewed by over 100 million viewers nationwide as well as internationally via DirecTV and Dish Network. The show can also be viewed through video [...]

Isotechnika names Daniel Park as CBO

Isotechnika Pharma (TSX:ISA) has appointed Daniel Park to the role of chief business officer, reporting directly to CEO Dr. Robert Foster. Mr. Park will oversee all business development operations at Isotechnika, and will specifically help to lead licensing and partnership discussions and negotiations for voclosporin. He will also maintain his position as executive VP of [...]

Isotechnika partner starts uveitis Phase 3 trial

Isotechnika Pharma’s (TSX: ISA) partner Lux Biosciences has begun an additional Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability. The six-month study will involve 150 patients in North America and Europe with active non-infectious intermediate, posterior, or pan-uveitis. Lux is conducting this additional [...]

Isotechnika receives financing for Phase 3 trial

Isotechnika Pharma (TSX:ISA) has finalized the development, distribution and license agreement with ILJIN Life Science, a member of the ILJIN Group of South Korea, in order to finance a pivotal Phase 3 trial of voclosporin for the prevention of kidney transplant rejection. Isotechnika will now receive a license fee of $4.5-million plus proceeds of $2.375-million from [...]

Isotechnika licenses voclosporin to ILJIN Life

Isotechnika Pharma (TSX:ISA) has entered into a development, distribution and licence agreement with ILJIN Life Science, a member of the ILJIN Group of South Korea, for the further clinical and commercial development of its voclosporin drug. Isotechnika has granted ILJIN an exclusive license to voclosporin for transplant and autoimmune indications for the U.S. and other [...]

Lux-Isotechnika get complete response letter from FDA

Isotechnika Pharma’s (TSX:ISA) partner, Lux Biosciences, has received a complete response letter from the FDA about its new drug application for voclosporin in the treatment of non-infectious uveitis, involving the intermediate or posterior segments of the eye. The FDA has requested additional information and recommended that an additional clinical trial be conducted in order to [...]

FDA cancels meeting but review of Isotechnika’s voclosporin continues

The FDA has cancelled a June 28 dermatology and ophthalmology drugs advisory committee review of a new drug application by Isotechnika Pharma’s (TSX:ISA) partner Lux Biosciences for their voclosporin drug as a treatment of non-infectious uveitis. On its website, the FDA said the meeting was cancelled to allow time for the “resolution of several outstanding [...]

Isotechnika has a powerhouse franchise in voclosporin

Dr. Robert Foster still longs to make Isotechnika’s (TSX: ISA) lead drug, voclosporin, the standard of care in the field of preventing organ rejection in transplantation surgery. This may seem somewhat unusual, since voclosporin is currently being considered by regulators in North America and Europe to treat uveitis, a chronic inflammation of the eye that [...]

EMA accepts Isotechnika-Lux filing for eye drug

The European Medicines Agency has accepted a marketing application filed by Isotechnika Pharma’s (TSX:ISA) partner, Lux Biosciences, for voclosporin to treat non-infectious uveitis involving the posterior segment of the eye, the fourth leading cause of legal blindness in the industrialized world. “With the EMA acceptance of the dossier we now expect the review process to [...]

« Previous Page